Targets › PML
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Nov 2028.
Functions via its association with PML-nuclear bodies (PML-NBs) in a wide range of important cellular processes, including tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense mechanisms. Acts as the scaffold of PML-NBs allowing other proteins to shuttle in and out, a process which is regulated by SUMO-mediated modifications and interactions. (UniProt, P29590)
Open in Phaseline: the race on PML, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Instituto do Cancer do Estado de São Paulo | Realgar-Indigo Naturalis Formulation (Oral Arsenic) Arsenic trioxide induces differentiation and apoptosis of acute promyelocytic leukemia cel | PML, RARA | Phase 2 | Acute Promyelocytic Leukemia (APL) | Nov 2028 |
Acute Promyelocytic Leukemia (APL) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.